AR010910A1 - PHARMACEUTICAL COMPOSITIONS CONTAINING PROPANAMINE AND CYCLODEXTRIN DERIVATIVES, THE INCLUSION COMPLEXES THAT MAKE THEM, A PROCEDURE FOR THE PREPARATION OF THESE LASTS, AND A METHOD OF ANTI-DEPRESSIVE TREATMENT USING THE PHARMACEUTICAL COMPOSITIONS. - Google Patents
PHARMACEUTICAL COMPOSITIONS CONTAINING PROPANAMINE AND CYCLODEXTRIN DERIVATIVES, THE INCLUSION COMPLEXES THAT MAKE THEM, A PROCEDURE FOR THE PREPARATION OF THESE LASTS, AND A METHOD OF ANTI-DEPRESSIVE TREATMENT USING THE PHARMACEUTICAL COMPOSITIONS.Info
- Publication number
- AR010910A1 AR010910A1 ARP980101328A ARP980101328A AR010910A1 AR 010910 A1 AR010910 A1 AR 010910A1 AR P980101328 A ARP980101328 A AR P980101328A AR P980101328 A ARP980101328 A AR P980101328A AR 010910 A1 AR010910 A1 AR 010910A1
- Authority
- AR
- Argentina
- Prior art keywords
- cyclodextrin
- gamma
- pharmaceutical compositions
- propanamine
- preparation
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 230000001430 anti-depressive effect Effects 0.000 title abstract 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 title abstract 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title abstract 2
- 229920000858 Cyclodextrin Polymers 0.000 abstract 10
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 abstract 6
- 229940080345 gamma-cyclodextrin Drugs 0.000 abstract 5
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 abstract 3
- 229940043377 alpha-cyclodextrin Drugs 0.000 abstract 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract 3
- 229960004853 betadex Drugs 0.000 abstract 3
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000000935 antidepressant agent Substances 0.000 abstract 1
- 229940005513 antidepressants Drugs 0.000 abstract 1
- 229940097362 cyclodextrins Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- -1 hydroxypropyl alpha- Chemical compound 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- WIQRCHMSJFFONW-UHFFFAOYSA-N norfluoxetine Chemical compound C=1C=CC=CC=1C(CCN)OC1=CC=C(C(F)(F)F)C=C1 WIQRCHMSJFFONW-UHFFFAOYSA-N 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Abstract
Una composicion farmacéutica, un procedimiento para su preparacion y un método de tratamiento antidepresivo utilizando dicha composicion que contieneuna propanamina de la formula general I -en la que R significa hidrogeno o metilo o cualquiera de sus isomeros opticos y/o sales aceptables desde el puntode vista farmacologico, junto con una ciclodextrina, preferentemente en forma de un complejo de inclusion. Dicha composicion puede además contener opcionalmente, sustancias auxiliares y adicionales aceptables en productos farmacéuticos para la administracion oral, parenteral,transdermal, rectal u otros usos medicinales. Las ciclodextrinas preferidas son las gama-ciclodextrina, una alfa-, beta- o gama-ciclodextrina metilada, una alfa-,beta- o gama-ciclodextrina hidroxipropilada, un polimero de alfa-, beta- o gama-ciclodextrina ionico y soluble de agua, una alfa-, beta- o gama-ciclodextrina maltosilada. La invencion también cubrelos complejos de inclusion y su preparacion. El complejo de inclusion preferido es el que contiene (), (-) o (+) gama-[4-(trifluorometil)-fenoxi]benceno-propanamina y gama-ciclodextrina.A pharmaceutical composition, a method for its preparation and an antidepressant treatment method using said composition containing a propanamine of the general formula I - in which R means hydrogen or methyl or any of its optical isomers and / or salts acceptable from the point of view pharmacologically, together with a cyclodextrin, preferably in the form of an inclusion complex. Said composition may also optionally contain auxiliary and additional substances acceptable in pharmaceuticals for oral, parenteral, transdermal, rectal administration or other medicinal uses. Preferred cyclodextrins are the gamma-cyclodextrin, an alpha-, beta- or methylated gamma-cyclodextrin, a hydroxypropyl alpha-, beta- or gamma-cyclodextrin, a water soluble and ionic alpha-, beta- or gamma-cyclodextrin polymer , a maltosylated alpha-, beta- or gamma-cyclodextrin. The invention also covers inclusion complexes and their preparation. The preferred inclusion complex is that containing (), (-) or (+) gamma- [4- (trifluoromethyl) -phenoxy] benzene-propanamine and gamma-cyclodextrin.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU9700632A HUP9700632A3 (en) | 1997-03-24 | 1997-03-24 | Pharmaceutical compositions containing propylamine derivative and cyclodextrine and process for producing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR010910A1 true AR010910A1 (en) | 2000-07-12 |
Family
ID=89994898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980101328A AR010910A1 (en) | 1997-03-24 | 1998-03-24 | PHARMACEUTICAL COMPOSITIONS CONTAINING PROPANAMINE AND CYCLODEXTRIN DERIVATIVES, THE INCLUSION COMPLEXES THAT MAKE THEM, A PROCEDURE FOR THE PREPARATION OF THESE LASTS, AND A METHOD OF ANTI-DEPRESSIVE TREATMENT USING THE PHARMACEUTICAL COMPOSITIONS. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0969874A1 (en) |
| JP (1) | JP2002514210A (en) |
| AR (1) | AR010910A1 (en) |
| AU (1) | AU6848198A (en) |
| HR (1) | HRP980155A2 (en) |
| HU (1) | HUP9700632A3 (en) |
| WO (1) | WO1998042382A1 (en) |
| ZA (1) | ZA982457B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7091192B1 (en) * | 1998-07-01 | 2006-08-15 | California Institute Of Technology | Linear cyclodextrin copolymers |
| AU5535900A (en) * | 1999-07-01 | 2001-01-22 | Italfarmaco S.P.A. | Complexes of paroxetine, with cyclodextrins or cyclodextrin derivatives |
| CA2497792C (en) | 2002-09-06 | 2014-08-05 | Insert Therapeutics, Inc. | Cyclodextrin-based polymers for therapeutics delivery |
| EP1594515A4 (en) * | 2003-02-03 | 2009-05-27 | Supernus Pharmaceuticals Inc | Drug formulation and delivery using crystalline methylated cyclodextrins |
| US20080176958A1 (en) | 2007-01-24 | 2008-07-24 | Insert Therapeutics, Inc. | Cyclodextrin-based polymers for therapeutics delivery |
| US20140094432A1 (en) | 2012-10-02 | 2014-04-03 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
| EP3453390B1 (en) | 2016-05-06 | 2024-02-14 | Biodynamic Research Foundation | Polymerized drug-containing pharmaceutical composition |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| WO1991013100A1 (en) * | 1990-03-02 | 1991-09-05 | Australian Commercial Research & Development Limited | Cyclodextrin compositions and methods for pharmaceutical and industrial applications |
-
1997
- 1997-03-24 HU HU9700632A patent/HUP9700632A3/en unknown
-
1998
- 1998-03-23 AU AU68481/98A patent/AU6848198A/en not_active Abandoned
- 1998-03-23 WO PCT/HU1998/000028 patent/WO1998042382A1/en not_active Application Discontinuation
- 1998-03-23 EP EP98913968A patent/EP0969874A1/en not_active Withdrawn
- 1998-03-23 JP JP54325498A patent/JP2002514210A/en active Pending
- 1998-03-23 ZA ZA982457A patent/ZA982457B/en unknown
- 1998-03-23 HR HRP9700632A patent/HRP980155A2/en not_active Application Discontinuation
- 1998-03-24 AR ARP980101328A patent/AR010910A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HU9700632D0 (en) | 1997-05-28 |
| AU6848198A (en) | 1998-10-20 |
| HRP980155A2 (en) | 1998-12-31 |
| HUP9700632A3 (en) | 1999-10-28 |
| ZA982457B (en) | 1998-09-23 |
| WO1998042382A1 (en) | 1998-10-01 |
| HUP9700632A2 (en) | 1998-12-28 |
| JP2002514210A (en) | 2002-05-14 |
| EP0969874A1 (en) | 2000-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR012927A1 (en) | A PHARMACEUTICAL COMPOSITION, A PHARMACEUTICAL DOSAGE FORM, THE USE OF SUCH COMPOSITION FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND A FORM OF PHARMACEUTICAL PRESENTATION FOR COMMERCIAL SALE | |
| CY1110906T1 (en) | PHARMACEUTICAL COMPOSITION FOR NON-ADMINISTRATION OF FENTANYL | |
| PA8453201A1 (en) | PHARMACEUTICAL FORMULATIONS CONTAINING VORICONAZOLE | |
| CY1107294T1 (en) | LOCAL COMPOSITION CONTAINING A VITAMIN D OR A VERSION OF VITAMIN D AND A VULNERABLE CYTICOSTEROID | |
| AR021844A1 (en) | ARIL-SUBSTITUTED PROPANOLAMINE DERIVATIVES, PROCEDURES FOR PREPARATION, MEDICATIONS CONTAINING THESE COMPOUNDS AND THEIR USE | |
| HN2003000407A (en) | NEW DERIVATIVES OF AROMATIC FLUOROGLYCOSISES, MEDICINES CONTAINING THESE COMPOUNDS AND THEIR USES. | |
| CY1115386T1 (en) | A combination of azelastin and mometasone | |
| ES2144192T3 (en) | NEW DERIVATIVES OF 1-PHENYL-2-DIMETHYL-AMINO-METHYL-CICLOHEXAN-1-OL, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
| ES2176206T3 (en) | DERIVATIVES OF CYCLODEXTRINES SHOWING INCREASED SOLUBILITY IN WATER AND USING THEMSELVES. | |
| DE60039125D1 (en) | 9- (PIPERAZINYL ALKYL) CARBAZOLE AS BAX MODULATORS | |
| CY1105465T1 (en) | DOSAGE FORM PEPILAMVANOUS LIQUID PREPARATION | |
| DK0738152T3 (en) | Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as chemopreventive and chemotherapeutic agents for colon cancer | |
| ES2151083T3 (en) | ORAL COMPOSITIONS CONTAINING ONDANSETRON. | |
| BR9713147A (en) | Benzamidoaldehyde, use of it, benzamide, and drug preparation for oral, parenteral or intraperitoneal administration. | |
| AR018197A1 (en) | PIPERIDINE COMPOUNDS, A PROCEDURE FOR THE PREPARATION, A COMPOSITION AND USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT | |
| PT1073467E (en) | CO-SOLVENT FORMULATIONS THAT UNDERSTAND A VITAMIN D COMPOSITION. | |
| AR012504A1 (en) | USE OF TETRAHYDROPYRIDINE DERIVATIVES, FOR THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DISEASES WHICH CAUSE A DEMELINATION. | |
| AR010910A1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING PROPANAMINE AND CYCLODEXTRIN DERIVATIVES, THE INCLUSION COMPLEXES THAT MAKE THEM, A PROCEDURE FOR THE PREPARATION OF THESE LASTS, AND A METHOD OF ANTI-DEPRESSIVE TREATMENT USING THE PHARMACEUTICAL COMPOSITIONS. | |
| AR021843A1 (en) | DERIVATIVES OF PROPANOLAMINE SUBSTITUTED WITH HETEROCICLES, PROCEDURE FOR THEIR PREPARATION, AND ITS USE. | |
| EA200100226A1 (en) | TOPICAL, CONTAINING NIMESULIDE PHARMACEUTICAL COMPOSITIONS | |
| AR035006A1 (en) | DERIVATIVE OF NAFTIRIDIN-DIBENZO [A, D] CICLOHEPTENO-10-ACETICO, PHARMACEUTICAL COMPOSITION, AND THE USE OF THAT DERIVATIVE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT. | |
| BR0114380A (en) | 1-Aminobutan-3-ol-substituted derivatives | |
| AR029666A1 (en) | USE OF (+) -ALFA- (2,3-DIMETOXIFENIL) -1- [2- (4-FLUOROPHENYL) ETHYL] -4-PIPERIDINMETHANOL OR ITS DRUG FOR THE MANUFACTURE OF A MEDICINAL PRODUCT IN THE TREATMENT OF SYMPTOMS OF DEMENTIA AND OF PSYCHOSIS INDUCED BY DOPAMINE | |
| ES2189072T3 (en) | NEW BENZO-HETEROCICLIC CYCLALKINS, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
| CY1106712T1 (en) | 5-AMINO-1-PENTENE-3-OLE SUBSTITUTED DERIVATIVES |